Eagle Pharmaceuticals Stock News

Equities analysts predict that Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) will report $48.01 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Eagle Pharmaceuticals earnings, with estimates ranging from $46.51 million to $49.50 million. Eagle Pharmaceuticals reported sales of $49.92 million in the same quarter last year, which []

Charles Schwab Investment Management Inc. lifted its stake in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) by 4.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 80,656 shares of the specialty pharmaceutical companys stock after purchasing an additional 3,653 shares during the quarter. []

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present virtually at the Piper Sandler 33rd Annual Healthcare Conference 2021 as follows: Date: Monday, November 22, 2021 Time/On Demand: 10:00AM ET Webcast: https://pipersandler.zoom.us/rec/play/gKb-8Uf5FTyDI-TguX2M-ziZvOHQuT9LOFMBE7BTLwbNzRNQz-5dpn0wd3T7bdN8bc14RITsJSMvcBE

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chie

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tariff on Q3 2021 Results - Earnings Call Transcript

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -35.63% and -14.66%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the s

Endo: A Win In California But Equity Value Still A Question

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2021 third quarter financial resu

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) will host an investor event, led by Scott Tarriff, Chief Executive Officer, and Jud

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chie

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. District Court for the District of Delaware held that

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Patent and Trademark Office has granted the Company U

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has entered into a worldwide licensing agreement with Combi

Eagle Pharmaceuticals Inc (NASDAQ: EGRX) has entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH for the commercial rights to its product, Landiolol, in the U.S.  Landiolol, a